The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Expression profiling reveals off-target gene regulation by RNAi
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., & Linsley, P. S. (2003) · Nature Biotechnology · doi:10.1038/nbt831 · Cited by 2,370 · cited 1×
“An important consideration for siRNA-mediated inhibition of gene expression is whether the observed effects are specific and not due to nonspecific “off target” effect”
BackgroundMicroRNA-Directed Cleavage of HOXB8 mRNA
Yekta, S., Shih, I.-H., & Bartel, D. P. (2004) · Science · doi:10.1126/science.1097434 · Cited by 1,702
Cleavage of Scarecrow-like mRNA Targets Directed by a Class of Arabidopsis miRNA
Llave, C., Xie, Z., Kasschau, K. D., & Carrington, J. C. (2002) · Science · doi:10.1126/science.1076311 · Cited by 1,627 · cited 1×
“Determination of in vivo mechanism of action To prove that the in vivo activity was due to siRNA-directed cleavage, we characterized specific mRNA cleavage products using a modified 5′-RACE (rapid amplification of cDNA ends) technique previously used to demonstrate microRNA (miRNA)-directed mRNA cleavage in plant”
MethodRNA interference targeting Fas protects mice from fulminant hepatitis
Song, E., Lee, S.-K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., & Lieberman, J. (2003) · Nature Medicine · doi:10.1038/nm828 · Cited by 1,110
Induction of an interferon response by RNAi vectors in mammalian cells
Bridge, A. J., Pebernard, S., Ducraux, A., Nicoulaz, A.-L., & Iggo, R. (2003) · Nature Genetics · doi:10.1038/ng1173 · Cited by 961
Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 724
Reich, S. J., Fosnot, J., Kuroki, A. M., Tang, W., Yang, X., Maguire, A. M., Bennett, J., & Tolentino, M. J. (2003) · PubMed · Cited by 441
siRNA relieves chronic neuropathic pain
Dorn, G. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh044 · Cited by 381
Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells
Lorenz, C., Hadwiger, P., John, M., Vornlocher, H.-P., & Unverzagt, C. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.07.018 · Cited by 338
Self-citation
Cited by
Items 201–215 of 215
Chen, L., Gu, T., Li, B., Li, F., Ma, Z., Zhang, Q., Cai, X., & Lu, L. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.06.011 · Cited by 60
Guidelines for experiments using antisense oligonucleotides and double-stranded RNAs
Gagnon, K. T., & Corey, D. R. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0772 · Cited by 59
Takahashi, H., Wang, Y., & Grainger, D. W. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.019 · Cited by 58
“(32,33) In order to overcome several delivery challenges for siRNA in therapeutics, several approaches have been used, including conjugating siRNA with cholesterol (34), and delivery using cationic liposomes (35) and polymer carriers.”
MethodTherapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Sun, Y., Zhao, Y., Zhao, X., Lee, R. J., Teng, L., & Zhou, C. (2017) · Molecules · doi:10.3390/molecules22101724 · Cited by 56
Wang, X., Sommerfeld, M. R., Jahn‐Hofmann, K., Cai, B., Filliol, A., Remotti, H. E., Schwabe, R. F., Kannt, A., & Tabas, I. (2019) · Hepatology Communications · doi:10.1002/hep4.1405 · Cited by 56
Hoogenboezem, E. N., Patel, S. S., Lo, J. H., Cavnar, A. B., Babb, L. M., Francini, N., Gbur, E. F., Patil, P., Colazo, J. M., Michell, D. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45609-0 · Cited by 52
Mouse phenogenomics: the fast track to “systems metabolism
Argmann, C. A., Chambon, P., & Auwerx, J. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.11.002 · Cited by 51
microRNA-132 regulates gene expression programs involved in microglial homeostasis
Walgrave, H., Penning, A., Tosoni, G., Snoeck, S., Davie, K., Davis, E., Wolfs, L., Sierksma, A., Mars, M., Bu, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106829 · Cited by 41
Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?
Gherardini, L., Bardi, G., Gennaro, M., & Pizzorusso, T. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1310-8 · Cited by 28
Nucleic acid therapies for cystic fibrosis
Sasaki, S., & Guo, S. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0696 · Cited by 24
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Wang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10
RNA interference to target lipid disorders
Rondinone, C. M. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ff861e · Cited by 2
Small Interfering RNAs (siRNAs)
Tosar, J. P. (2024) · Topics in Medicinal Chemistry · doi:10.1007/7355_2024_171 · Cited by 1
Metadata
- Authors
- Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R. K., Racie, T., Rajeev, K. G., Röhl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., & Vornlocher, H.-P.
- Venue
- Nature
- Published
- 2004-11
- Volume
- 432
- Issue
- 7014
- Pages
- 173-178
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2116424844
- Cited by
- 2,183
- References
- 22
- FWCI
- 51.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.